Genmab As Stock Buy Hold or Sell Recommendation
| GNMSF Stock | USD 212.50 4.81 2.32% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Genmab AS is 'Strong Sell'. Macroaxis provides Genmab AS buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GNMSF positions.
Check out Genmab AS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide. Note, we conduct extensive research on individual companies such as Genmab and provide practical buy, sell, or hold advice based on investors' constraints. Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Genmab |
Execute Genmab AS Buy or Sell Advice
The Genmab recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Genmab AS. Macroaxis does not own or have any residual interests in Genmab AS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Genmab AS's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Genmab AS Trading Alerts and Improvement Suggestions
| Genmab AS generated a negative expected return over the last 90 days |
Genmab AS Returns Distribution Density
The distribution of Genmab AS's historical returns is an attempt to chart the uncertainty of Genmab AS's future price movements. The chart of the probability distribution of Genmab AS daily returns describes the distribution of returns around its average expected value. We use Genmab AS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Genmab AS returns is essential to provide solid investment advice for Genmab AS.
| Mean Return | -0.33 | Value At Risk | -4.83 | Potential Upside | 3.34 | Standard Deviation | 2.89 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Genmab AS historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Genmab AS Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Genmab AS or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Genmab AS's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Genmab pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | 0.26 | |
σ | Overall volatility | 2.93 | |
Ir | Information ratio | -0.16 |
Genmab AS Volatility Alert
Genmab AS exhibits very low volatility with skewness of -0.64 and kurtosis of 1.12. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Genmab AS's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Genmab AS's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Genmab AS Fundamentals Vs Peers
Comparing Genmab AS's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Genmab AS's direct or indirect competition across all of the common fundamentals between Genmab AS and the related equities. This way, we can detect undervalued stocks with similar characteristics as Genmab AS or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Genmab AS's fundamental indicators could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Genmab AS to competition |
| Fundamentals | Genmab AS | Peer Average |
| Return On Equity | 0.24 | -0.31 |
| Return On Asset | 0.1 | -0.14 |
| Profit Margin | 0.47 % | (1.27) % |
| Operating Margin | 0.38 % | (5.51) % |
| Current Valuation | 26.41 B | 16.62 B |
| Shares Outstanding | 65.96 M | 571.82 M |
| Shares Owned By Institutions | 49.90 % | 39.21 % |
| Price To Earning | 39.08 X | 28.72 X |
| Price To Book | 7.94 X | 9.51 X |
| Price To Sales | 2.45 X | 11.42 X |
| Revenue | 8.48 B | 9.43 B |
| Gross Profit | 8.48 B | 27.38 B |
| EBITDA | 4.24 B | 3.9 B |
| Net Income | 3.01 B | 570.98 M |
| Cash And Equivalents | 21.61 B | 2.7 B |
| Cash Per Share | 330.53 X | 5.01 X |
| Total Debt | 634 M | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 13.11 X | 2.16 X |
| Book Value Per Share | 408.67 X | 1.93 K |
| Cash Flow From Operations | 2.23 B | 971.22 M |
| Earnings Per Share | 12.00 X | 3.12 X |
| Price To Earnings To Growth | 1.20 X | 4.89 X |
| Target Price | 383.57 | |
| Number Of Employees | 1.56 K | 18.84 K |
| Beta | 0.67 | -0.15 |
| Market Capitalization | 26.78 B | 19.03 B |
| Total Asset | 24.63 B | 29.47 B |
| Retained Earnings | (3.96 B) | 9.33 B |
| Working Capital | 3.72 B | 1.48 B |
| Current Asset | 4.14 B | 9.34 B |
| Current Liabilities | 419 M | 7.9 B |
| Z Score | 25.2 | 8.72 |
Genmab AS Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Genmab . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Genmab AS Buy or Sell Advice
When is the right time to buy or sell Genmab AS? Buying financial instruments such as Genmab Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Genmab AS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.